Management of Carboplatin Sensitivity in Chemotherapy Patients

Understanding Carboplatin Hypersensitivity

Carboplatin hypersensitivity reactions occur in 1-46% of patients, with risk increasing significantly after multiple exposures, according to the Journal of Allergy and Clinical Immunology 1, 3
The National Comprehensive Cancer Network recommends assessing patient's renal function, performance status, and history of medication sensitivities before initiating carboplatin therapy 4
Patients with BRCA1/BRCA2 mutations appear to have higher risk for carboplatin HSRs and may experience reactions during desensitization, as reported by the Journal of Allergy and Clinical Immunology 5

Skin testing can help identify patients at risk when performed between treatments, using appropriate non-irritating concentrations, as recommended by the Journal of Allergy and Clinical Immunology 1, 3, 5

For patients with confirmed immediate HSRs, the Journal of Allergy and Clinical Immunology recommends assessing reaction severity and considering skin testing 1, 5
Desensitization protocol should be implemented when carboplatin is the preferred therapy, with options including standard 12-step protocol, modified 13-step protocol, and simplified 1-bag protocol, as reported by the Journal of Allergy and Clinical Immunology 1, 2, 6
The Journal of Allergy and Clinical Immunology suggests considering alternative platinum agents, with cross-reactivity rates of 7% between carboplatin and cisplatin, and 37% between carboplatin and oxaliplatin 1, 3, 7

Premedication alone does not prevent recurrence of HSRs or anaphylaxis in sensitized patients, according to the Journal of Allergy and Clinical Immunology 7

The National Comprehensive Cancer Network recommends counseling patients about the risk of HSRs, educating about symptoms, and ensuring treatment by staff trained in managing reactions 4
Monitoring for myelosuppression, dehydration, electrolyte loss, and end-organ toxicities after each cycle is crucial, as reported by the National Comprehensive Cancer Network 4

Empiric desensitization without skin testing is a safe approach when testing is not feasible, according to the Journal of Allergy and Clinical Immunology 6
Desensitization has been shown not to increase overall healthcare costs and maintains equivalent or superior life expectancy compared to alternative treatments, as reported by the Journal of Allergy and Clinical Immunology 6